Eli Lilly to insulin price-hike critics: Humalog's sticker grew 52%, but net dropped by 8%

25th March 2019 Uncategorised 0

Eli Lilly is under the gun for insulin price hikes, facing lawsuits, congressional scrutiny and general public outcry. But the drugmaker has repeatedly said it’s not profiting off those increases, and in its new annual report, it offers up some stats to bolster that case.

More: Eli Lilly to insulin price-hike critics: Humalog's sticker grew 52%, but net dropped by 8%
Source: fierce